Literature DB >> 10357495

Data and safety monitoring in the Concorde and Alpha trials.

P Armitage1.   

Abstract

Concorde was a randomized trial to compare immediate and deferred zidovudine (AZT) treatment for persons with asymptomatic HIV infection. Alpha was a randomized trial to compare the efficacy of two doses of didanosine (ddI), in persons with symptomatic HIV disease who were intolerant of zidovudine. The two trials overlapped in time, and a single Data and Safety Monitoring Committee (DSMC) monitored accumulating data from both trials. This paper describes the deliberations of the DSMC and its recommendations to the parent steering committee during the course of each trial. In the discussion on Concorde, I draw attention to the problems of interpreting early survival data and trends in surrogate markers. With Alpha, interest focusses on the conflicting considerations that arose in discussions about possible termination at an interim stage.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10357495     DOI: 10.1016/s0197-2456(99)00005-7

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  3 in total

1.  The evolution of ways of deciding when clinical trials should stop recruiting. Interview by Iain Chalmers.

Authors:  Peter Armitage
Journal:  J R Soc Med       Date:  2014-01       Impact factor: 5.344

2.  External data required timely response by the Trial Steering-Data Monitoring Committee for the NALoxone InVEstigation (N-ALIVE) pilot trial.

Authors:  Sheila M Bird; John Strang; Deborah Ashby; John Podmore; J Roy Robertson; Sarah Welch; Angela M Meade; Mahesh K B Parmar
Journal:  Contemp Clin Trials Commun       Date:  2017-03

3.  When enough is enough: how the decision was made to stop the FEAST trial: data and safety monitoring in an African trial of Fluid Expansion As Supportive Therapy (FEAST) for critically ill children.

Authors:  Jim Todd; Robert S Heyderman; Philippa Musoke; Tim Peto
Journal:  Trials       Date:  2013-03-26       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.